+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Retinoic Acid Receptor Beta - Pipeline Review, H2 2019

  • ID: 4866586
  • Drug Pipelines
  • November 2019
  • Region: Global
  • 77 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • 3SBio Inc
  • Advent Therapeutics Inc
  • Orphanix GmbH
  • Ortho Dermatologics Inc
  • Phosphagenics Ltd
  • Promius Pharma LLC
  • MORE
Retinoic Acid Receptor Beta - Pipeline Review, H2 2019

Summary

According to the recently published report 'Retinoic Acid Receptor Beta - Pipeline Review, H2 2019'; Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) pipeline Target constitutes close to 16 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes.

Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Retinoic acid receptor beta (RARB) is a nuclear receptor that is encoded by the RARB gene. RARB bind as heterodimers to the target response elements in response to their ligands (all-trans or 9-cis retinoic acid) and gene expression in various biological processes. In the absence or presence of hormone ligand, acts mainly as anregulate activator of gene expression due to weak binding to co-repressors. It is required for skeletal growth, matrix homeostasis and growth plate functions.

The report 'Retinoic Acid Receptor Beta - Pipeline Review, H2 2019' outlays comprehensive information on the Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 2, 6, 2, 4 and 1 respectively. Similarly, the universities portfolio in Phase I stages comprises 1 molecules, respectively. Report covers products from therapy areas Dermatology, Gastrointestinal, Respiratory, Central Nervous System, Hematological Disorders, Immunology, Metabolic Disorders, Oncology and Ophthalmology which include indications Acne Vulgaris, Bronchopulmonary Dysplasia, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Acute Promyelocytic Leukemia, Breast Cancer, Germ Cell Tumors, Hyperlipidemia, Inflammatory Bowel Disease, Myelodysplastic Syndrome, Neuroblastoma, Neutropenia, Non Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH), Psoriasis, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Retinopathy Of Prematurity, Sarcomas, Spinal Cord Injury, Traumatic Nerve Injury and Type 2 Diabetes.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB)
  • The report reviews Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • 3SBio Inc
  • Advent Therapeutics Inc
  • Orphanix GmbH
  • Ortho Dermatologics Inc
  • Phosphagenics Ltd
  • Promius Pharma LLC
  • MORE
Introduction
Report Coverage
Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Overview
Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Companies Involved in Therapeutics Development
3SBio Inc
Advent Therapeutics Inc
Bausch Health Companies Inc
Lee's Pharmaceutical Holdings Ltd
Orphanix GmbH
Ortho Dermatologics Inc
Phosphagenics Ltd
Promius Pharma LLC
Sol-Gel Technologies Ltd
Sunny BioDiscovery Inc
Sveikatal Inc
TherapyX Inc
Toko Pharmaceutical Industries Co Ltd
Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Drug Profiles
(adapalene + benzoyl peroxide + clindamycin phosphate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(adapalene + clindamycin hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(benzoyl peroxide + tretinoin) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(benzoyl peroxide + tretinoin) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(clindamycin phosphate + tretinoin) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(TPX-6001 + tretinoin) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AC-261066 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
alitretinoin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KCL-286 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SBD-073 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tamibarotene - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tazarotene - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tazarotene - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tretinoin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tretinoin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vitamin A palmitate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vitamin A palmitate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Dormant Products
Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Discontinued Products
Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Product Development Milestones
Featured News & Press Releases
Oct 24, 2019: Syros Announces new data from phase 2 trial of SY-1425 in combination with azacitidine demonstrating high response rates, rapid onset of action and favorable tolerability profile in RARA-Positive Newly Diagnosed Unfit AML Patients
Oct 15, 2019: Bausch Health's Ortho Dermatologics business to present data on tazarotene at The Fall Clinical Dermatology Conference
Oct 15, 2019: Bausch Health's Ortho Dermatologics business to present data on acne drug tretinoin at The Fall Clinical Dermatology Conference
Aug 07, 2019: Ortho Dermatologics announces U.S. FDA filing acceptance for IDP-123 treatment for Acne Vulgaris in lotion form
Aug 01, 2019: Syros highlights key accomplishments and provides milestone update on SY-1425
Jul 09, 2019: GSK's Alitoc becoming salvation treatment for chronic hand eczema patients
Apr 15, 2019: Sol-Gel Technologies announces 50% enrollment in pivotal phase III TWIN Program for the treatment of Acne Vulgaris
Jan 06, 2019: Syros provides update on its acute myeloid leukemia drug candidate SY-1425
Dec 17, 2018: Sol-Gel Technologies initiates pivotal phase III clinical program of TWIN for the treatment of acne vulgaris
Dec 02, 2018: Syros announces promising clinical data from ongoing phase 2 trial of SY-1425 in genomically defined AML and MDS patients at ASH Annual Meeting
Nov 01, 2018: Syros to present initial clinical data from combination cohorts in its ongoing phase 2 Trial of SY-1425 at ASH annual meeting
Oct 30, 2018: Bausch Health launches ALTRENO (tretinoin) Lotion, 0.05% in the United States
Oct 15, 2018: Bausch Health's ortho dermatologics business to present on ALTRENO During The Fall Clinical Dermatology Conference
Oct 11, 2018: Bausch Health announces publication of pivotal phase 3 efficacy and safety data on ALTRENO (tretinoin) Lotion, 0.05%, in the journal of drugs in dermatology
Sep 04, 2018: Sol-Gel Technologies provides program update for TWIN for the treatment of acne vulgaris
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by 3SBio Inc, H2 2019
Pipeline by Advent Therapeutics Inc, H2 2019
Pipeline by Bausch Health Companies Inc, H2 2019
Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2019
Pipeline by Orphanix GmbH, H2 2019
Pipeline by Ortho Dermatologics Inc, H2 2019
Pipeline by Phosphagenics Ltd, H2 2019
Pipeline by Promius Pharma LLC, H2 2019
Pipeline by Sol-Gel Technologies Ltd, H2 2019
Pipeline by Sunny BioDiscovery Inc, H2 2019
Pipeline by Sveikatal Inc, H2 2019
Pipeline by TherapyX Inc, H2 2019
Pipeline by Toko Pharmaceutical Industries Co Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019

List of Figures
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • 3SBio Inc
  • Advent Therapeutics Inc
  • Bausch Health Companies Inc
  • Lee's Pharmaceutical Holdings Ltd
  • Orphanix GmbH
  • Ortho Dermatologics Inc
  • Phosphagenics Ltd
  • Promius Pharma LLC
  • Sol-Gel Technologies Ltd
  • Sunny BioDiscovery Inc
  • Sveikatal Inc
  • TherapyX Inc
  • Toko Pharmaceutical Industries Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll